Evidence Level
Berberine is a natural plant alkaloid with demonstrated benefits for metabolic health. Yin et al. (2008) conducted a landmark trial showing that berberine lowers fasting blood glucose and HbA1c levels comparably to metformin in patients with type 2 diabetes mellitus. This finding was corroborated by Liang et al. (2019), who performed a systematic review and meta-analysis confirming berberine's efficacy in managing blood glucose levels. Additionally, Zhang et al. (2008) demonstrated that berberine provides combined benefits for both blood sugar control and dyslipidemia.
Recent studies have expanded the understanding of berberine's applications. Elahi Vahed et al. (2026) conducted a systematic review and meta-analysis of 23 randomized controlled trials (RCTs), concluding that berberine significantly reduces body weight, BMI, and waist circumference in adults with obesity. In the context of non-alcoholic fatty liver disease (NAFLD), Nie et al. (2024) found that berberine improves liver enzymes, lipid profiles, and insulin sensitivity in patients with mild adverse effects. Furthermore, Yang et al. (2023) reviewed 44 RCTs involving 4606 patients and concluded that berberine alone or in combination with statins reduces inflammation markers and NIHSS scores but does not significantly affect lipid levels in cardiovascular diseases.
Overall, berberine's clinical benefits are supported by robust evidence across multiple conditions, including diabetes, obesity, NAFLD, and cardiovascular diseases. Its mechanisms of action provide a clear biological basis for its therapeutic effects.